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ABSTRACT
Background: Adverse events and impairments associated with cancer and its treatments causes
worse outcomes. Increased incidence of renal diseases among cancer patients is of particular
concern. Objective: To determine the risk factors for renal disease in cancer patients and
compare healthcare costs, utilization and health-related quality of life (HRQoL) of cancer
patients with a renal disease and cancer patients without renal diseases. Methods: Medical
Expenditure Panel Survey files from 2009 – 2018 for cancer patients was used for this study.
Multiple logistic regression, generalized linear model, Poisson regression and multiple linear
regression for analyses after adjusting for demographic, socioeconomic and clinical factors.
Healthcare costs and utilization were determined in propensity score matched cohorts. Results:
Renal disease was present in 16% of cancer patients in United States. Cancer patients with renal
disease had higher adjusted mean healthcare expenditure from all sources of payments for
office-based visits to a provider ($7,881 vs $5.683), prescription medicines ($11,068 vs $6,764),
total medical cost ($37,283 vs $22,403) as compared to cancer patients without renal diseases.
Cancer patients with renal disease had higher median prescriptions filled (89 vs 57) and officebased visits to a physician (31 vs 21), higher PCS scores (40.52 vs 45.25) and MCS scores (50.31
vs 51.37). Conclusion: Cancer patients with renal disease had higher healthcare expenditure,
resource utilization and worse health-related quality of life than cancer patients without renal
disease, emphasizing the need of targeted care towards cancer patients with renal disease to
have better health outcomes.
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Chapter 1: BACKGROUND
Cancer is a major public health problem worldwide and is the second leading cause of
death in the United States.1 In 2018, 21% of the deaths recorded in the United States were
attributed to cancer.2 In 2021, it is estimated that prostate, lung and colorectal cancers will
account for 46% of all incident cases in men, with prostate cancer alone accounting for 26% of
diagnoses. For women, breast cancer, lung, and colorectal cancers will account for 50% of all new
diagnoses, with breast cancer alone accounting for 30% of female cancers.2 Cancer survivors are
projected to increase from 16.9 million people in 2019, to 22.2 million people in 2030. 3 The 5year survival rates from 2010 to 2016 was highest for prostate cancer (98%), melanoma of the
skin (93%), and female breast cancer (90%) and lowest for cancers of the pancreas (10%), liver
(20%), esophagus (20%), and lung (21%).4 The 5-year survival of cancer patients has increased
from 35% in 1950-1954 to 67.4% in 2010-2016.4 The increase in survival rate can be attributed to
factors like early detection practices, advances in curative therapy, increased life expectancy and
growth of an aging population.2 The consequences of increased survival include increasing
complications associated with the disease process.5
The economic burden of adverse events and complications in cancer patients is
substantial.6-10 The Agency for Healthcare Research and Quality’s (AHRQ) Medical Expenditure
Panel Survey estimated that for 2017, the direct medical costs for cancer, including all health care
expenditures, were $105.5 billion, of which 52% was spent on hospital outpatient or office-based
provider visits, 23.2% on inpatient hospital stays, and 19.6% on prescription medications. 11
Financial hardship can lead to lower quality of life, increased pain and greater symptom
burden.12-13 Due to treatment or disease burden, cancer patients have lower quality of life due
11

to physical symptoms like fatigue, pain, and nausea and vomiting, psychological symptoms like
anxiety and depression, and limitations and difficulty in performing daily activities. 14
Cancer treatments include systemic therapies such as chemotherapy, targeted therapy
and immunotherapies. These therapies are used alone or in combination with localized therapies
such as surgeries, radiation, heat or chemical ablation. Cancer therapies are effective but longterm cancer treatments can cause adverse effects and complications like anemia, nausea,
vomiting, neurotoxicity, nephrotoxicity.15,16 Management of adverse events and impairments
associated with cancer and its treatment is important because they influence adherence to
cancer therapies and quality of life.17 Increased incidence of kidney diseases among patients with
cancer is of particular concern because a decrease in renal function often requires dose
adjustment which may include decreasing the dose or stopping the use of certain
chemotherapeutic agents. This may delay or reduce the overall effectiveness of the cancer
treatment. Several mechanisms may underlie the high rate of renal disease in cancer patients
including drugs required to treat the malignancy and the nature of underlying disease causes
cancer patients to more likely to have renal diseases.18-22,

1.1 DRUG-INDUCED NEPHROPATHY
Kidneys are the main site of drug elimination for metabolites of systemic therapies.
Hence, they are exposed to high concentrations of metabolites of systemic therapies. Systemic
therapeutic agents such as ifosamide, tyrosine kinase inhibitors, premetrexed, cisplatin have
been associated with tubular toxicity.23 Nephrotoxicity of cisplatin, gemcitabine, mitomycin and
bevacizumab manifests as a glomerular disease in cancer patients as thrombotic
micoangiopathy.24-26 Immune checkpoint inhibitors like pembrolizumab and nivolumab causes
12

acute injury.83 Electrolyte abnormalities are caused by cetuximab, panitumumab, imatinib27-30
supportive care drugs like pain medications, antibiotics, antihistamines, antivirals, antacids,
bisphosphonates have been established to have some degree of nephrotoxicity.18
Chemotherapeutic drugs also cause nausea, vomiting, diarrhea and poor oral intake. These
adverse events cause volume depletion.19

1.2 LOCALIZED THERAPY ASSOCIATED KIDNEY DISEASE
Radiotherapy is often used in adjuvant to systemic therapies. Radiation has been
associated with renal injury. However due to long latency for radiotherapy induced kidney injury
and high prevalence of confounding factors, the magnitude of the effect of radiotherapy is
unclear.31 Obstruction of the urinary tract by malignancy can occur due in patients with
genitourinary cancer. Renal cell carcinoma is a common genitourinary malignancy. Patients are
commonly recommended for a partial and radical nephrectomy. Evidence suggests that these
surgeries increase the risk of AKI in short term and chronic kidney disease (CKD) both in long
term.32

1.3 INDIRECT CAUSES OF RENAL DISEASE
Antitumor activities of novel target therapies increase the risk of patients experiencing
tumor lysis syndrome. Tumor lysis syndrome leads to formation of uric acid crystals which causes
renal damage.20 Apart from this, tumor lysis syndrome also causes an imbalance of acid-base and
electrolytes in the bloodstream which affects kidneys. Patients with cancer are at a higher risk
for infections due to alterations in innate and adaptive immunity from the malignancy and
aggressive cancer therapies. 2.3 million hospital bed days and $3 billion were attributed to
infections in cancer patients and it is estimated to increase to 3.4 million hospital bed days and
13

$4.5 million expenditure.33 Cancer patients are 10 times more likely to develop sepsis compared
to the general population.34 20% of ICU admissions are cancer patients with sepsis being the
leading reason of admission. These complications increase the length of stay and overall costs.
Evidence suggests that AKI occurs in 19% of patients with moderate sepsis, 23% with severe
sepsis and 51% with septic shock.35–37 Previous literature has also suggested a link between
cardiovascular and renal disease where both have common risk factors. Patients with CKD have
a high prevalence of hypertension.21 Hepatorenal syndrome is another risk factor which causes
pre-renal AKI. 22
Common renal diseases in cancer patients include acute kidney injury and chronic renal
disease. Membranous Nephropathy is the most common type of renal disease associated with
solid tumors.38 IgA nephropathy, membranoproliferative glomerulonephritis and extra capillary
glomerulonephritis have also been reported, in case studies although less commonly than other
renal diseases mentioned previously.
With newer therapies which improve the overall survival of cancer patients, long-term
management of patients who develop renal diseases from their cancer treatment is essential.
Decrease in renal function often requires a dose adjustment which may include decreasing the
dose or stopping the use of certain chemotherapeutic agents which may delay or reduce the
overall effectiveness of the cancer treatment. This emphasizes the need for early detection and
intervention to alleviate the cause of renal disease. Studies in non-cancer patients with renal
diseases have shown longer hospitalization, increased hospital costs and lower quality of life. 39
Cancer and CKD are the costliest conditions for Part B Medicare beneficiaries and evidence
suggests that presence of renal disease in cancer patients increases length of stay, and
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mortality.40-42 We hypothesize in our study that cancer patients with renal disease would also
have higher healthcare utilization, expenditure and lower quality of life than cancer patients who
do not have renal disease.
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Chapter 2: LITERATURE REVIEW
A literature review was conducted to identify research articles which assesses the
economic burden and quality of life associated with renal disease in cancer patients. The review
and search were carried out in May 2020 in PubMed and CINAHL with a combination of keywords
and MeSH terms. The search query used was a combination of: “Kidney Diseases” [Mesh],
“Nephrotoxic*”, “Kidney toxic*”, “Renal toxic*”, "Observational Studies as Topic"[Mesh] “Cohort
Studies” [Mesh], “Observational Study” [Publication Type], “Neoplasms” [Mesh], “Cancer*”,
“malignan*”, “carcinoma*”, “metastat*” and “tumour*”. Titles and abstracts were screened.
The following inclusion and exclusion criteria were applied:
Inclusion Criteria:
1) Studies conducted in cancer patients over 18 years of age
2) Studies with specific renal outcomes
Exclusion Criteria:
1) Case reports and reviews
2) Studies where renal disease is a post-surgery complication
3) Studies which built and validated predictive models
4) Studies which tested interventions to treat renal diseases
5) Studies not conducted in United States
1,148 articles were retrieved from the database and their titles and abstracts were read and
1,131 articles were excluded based on the exclusion criteria. The full-texts of remaining articles
were accessed and read for including only eligible articles in the review. After reading the full
texts, 7 articles were excluded based on the exclusion criteria and 10 articles were selected for
16

the final review.43-52 These 10 articles are summarized in Table 1 which includes 7 articles with
the objective of estimating risk factors associated with renal diseases and 3 articles which aim at
estimating healthcare utilization and expenditure associated with renal diseases.

SCREENING

IDENTIFICATION

Figure 1: PRISMA flowchart for Literature Review

Studies identified through
database searching (N = 1,148)

Titles and abstracts screened
(N = 1,148)

INCLUDED

ELIGIBLITY

Articles excluded (N = 1,131)
• Cases and Reviews (N = 645)
• Non-Renal Outcomes (N = 289)
• Clinical Trials (N = 184)
• Studies not done in the US (N = 13)
Full text articles assessed for
eligibility (N = 17)

Articles selected for final
review
(N = 10)

•
•
•

Articles excluded (N = 7)
Cases and Reviews (N = 3)
Non-Renal Outcomes (N = 2)
Studies not done in the US (N = 2)
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Table 1: Literature from PUBMED and CINAHL summarized
SR. NO AUTHORS

OBJECTIVE

STUDIES ASSESSING RISK AND PREVALENCE
1 Li et al.
To examine the
43
association between
adjuvant
chemotherapy and
acute kidney injury
(AKI)

SAMPLE POPULATION
Elderly Medicare
enrollees with newly
diagnosed early- stage
breast cancer

2

Lahoti
et al.44

To estimate the
incidence of AKI and to
evaluate the risk factors
for AKI

3

Arellano
et al.45

To estimate the
prevalence of renal
impairment and
chronic kidney
disease (CKD)

4

Huang
et al.46

To assess kidney
function outcomes

Patients undergoing
surgery for renal cortical
tumor in cancer center

5

Qian et
al. 47

To estimate the
prevalence of renal
impairment and
chronic kidney
disease

Patients with multiple
myeloma

6

Salahud
een et

To determine
incidence rate,

Hospitalized patients
with cancer

Patients with acute
myelogenous leukemia
(AML) or high‐risk
myelodysplastic
syndrome (HR‐MDS)
undergoing induction
chemotherapy
Patients with bone
metastases from
solid tumors

RESULTS
Chemotherapy treated
patients are 2.73 times
more likely to have AKI
than untreated patients.
Incidence of AKI: Taxane >
Other > Anthracycline >
Cyclophosphamide/Methot
rexate/5-Fluorouracil
no AKI – 64%; Risk – 15%;
Injury – 10%; Failure – 11%

5-year prevalence of RI 43%. 46% CKD patients
received intravenous
bisphosphonates in the 12
months following their
confirming eGFR. 13% of
these patients received at
least one other
nephrotoxic agent during
that period
Patients who underwent
radical nephrectomy had a
higher risk (3.82 times) of
CKD than those who
underwent partial
nephrectomy
6-month prevalence after
multiple myeloma diagnosis:
RI – 47%, CKD – 27%
12 months after multiple
myeloma diagnosis:
RI – 54%, CKD – 39%
12% of the admitted patients
had AKI; Risk – 68%, Injury –
21%, Failure – 11%. Length
18

7

al.48

clinical correlates,
and outcomes of AKI

Lahoti
et al.49

To estimate the
incidence, outcomes,
and costs associated
with AKI

Hospitalized patients
with cancer

of stay (100%), cost (106%)
and odds of mortality (4.7fold) was significantly greater
AKI – 12.6%; risk – 6%;
injury – 3%; failure – 4%;
Each percent increase in
serum creatinine was
associated with a 0.16%
increase in cost

STUDIES ASSESSING HEALTHCARE UTILIZATION AND EXPENDITURE
8

Qian et
al.50

To estimate
healthcare resource
use and costs
associated
with RI

Patients with bone
metastases from
solid tumors

9

Bhowmi
k et al.

To estimate
healthcare resource
use and costs
associated
with CKD

Patients with
multiple myeloma

To compare
inpatient length of
stay and costs

Hospitalized
patients with
hematologic
malignancies

51

10. Candrill
i et al.
52

Outpatient services (38.4 vs
26.7); Emergency dept visits
(6.8 vs 3.9); Hospital
admission ($72,557 vs
$27,858); Total healthcare
cost ($142,267 vs $88,839)
No. of patients with an
admission (57.1% vs
32.1%); Frequency of
prescription fills (90.2 vs
66.9); Office visits (35.7 vs
30.1); Frequency of
Laboratory services (96.9
vs 66.4); Total healthcare
cost ($106,634 vs
$71,880);
ARF and RD - $44,619; ARF
and no RD - $25,638; no
ARF and no RD - $13,947

ARF – Acute Renal Failure; RD – Renal Dialysis; AKI – Acute Kidney Injury; CKD – Chronic Kidney
Disease; RI – Renal Impairment; eGFR – estimated Glomerular Filtration Rate;

STUDIES ASSESSING RISK AND PREVALENCE
A study by Li et al. examined the association between adjuvant chemotherapy and acute
kidney injury in elderly Medicare enrollees who were newly diagnosed with early-stage breast
cancer.43 They used the linked Surveillance, Epidemiology, and End Results (SEER)-Medicare
19

database and found that after adjusting for baseline characteristics, adjuvant chemotherapy
increased the risk of AKI by almost 3 times (HR = 2.69). They also found that AKI risk was highest
for patients who received only taxane-based chemotherapy (which included docetaxel or
paclitaxel) with a 6-month cumulative incidence of AKI of 2%. The risk was lower in patients who
received only anthracycline-based chemotherapy (0.7%) (included doxorubicin and epirubicin)
and only CMF regimen (0.5%) (included cyclophosphamide, methotrexate, and 5-fluorouracil).
The study by Lahoti et al. was done for patients with acute myelogenous leukemia or
high‐risk myelodysplastic syndrome who had developed AKI.44 They found that 36% of patients
had developed AKI (defined as >100% increase in serum creatinine).
The study by Arellano et al. in patients who had solid tumor metastasized to bones.45 They
found that 43% of the patients developed renal impairment (defined as at least one eGFR value
<60 mL/min per 1.73 m2). CKD prevalence (defined as at least 2 eGFR values <60 mL/min per 1.73
m2, at least 90 days apart) was found to be 35% in this patient population. Pamidronic and
zoledronic acids are intravenously administered bisphosphonates used to prevent bone
complications which are also nephrotoxic. They also found that 46% of the CKD patients had
received these intravenously administered bisphosphonates in the 12 months following their
confirming eGFR.
In patients with renal cancer, one of the common treatment options is nephrectomy.
Huang et al. found that the 3-year probability of not having a CKD (defined as GFR lower than 60
mL/min per 1·73 m2) was 80% after partial nephrectomy and 35% after radical nephrectomy.46
Qian et al suggests that 47% of patients developed renal impairment and 27% of patients
20

developed chronic kidney disease, 6 months after multiple myeloma diagnosis.47 54% of patients
developed renal impairment and 39% of patients developed chronic kidney disease 12 months
after multiple myeloma diagnosis.
Salahudeen et al. examined cancer patients admitted to the hospital.48 They found that
12% of cancer patients had AKI (defined as a two-fold increase in serum creatinine or >50%
decrease of eGFR). Diabetes, chemotherapy, hyponatremia, antibiotic therapy, intravenous
contrast and transfer to the ICU were found to be significant predictors of developing AKI in
hospitalized patients. The median length of hospital stay was 10 days for patients with AKI and 5
days for patients with AKI. Similarly, the hospital bill was significantly higher in patients with AKI
($82,835) than patients without AKI ($40,164).
Another study by Lahoti et al. in hospitalized cancer patients found the incidence rate of
AKI (defined as a two-fold increase in serum creatinine or >50% decrease of eGFR) in cancer
patients admitted to the ICU to be 12.6% for AKI where 6% were at risk, 3% with injury and 4%
with failure.49 They also found that each percent increase in serum creatinine was associated
with a 0.16% increase in cost.
STUDIES ASSESSING HEALTHCARE UTILIZATION AND EXPENDITURE
Qian et al. estimated the healthcare resource use and cost associated with renal
impairment (RI) in patients with bone metastases from primary tumor using an administrative
claims database.50 They found that total healthcare cost was $142,267 in patients with RI vs
$88,839 in patients without RI. Frequency of outpatient services used in patients with RI was 38.4
as compared to 26.7 in patients without RI. Frequency of other service (emergency department
21

visits, hospital admissions) used was also greater in the cohort with RI.
Similar results were found by Bhowmik et al. who looked at healthcare resource use and
cost for CKD in multiple myeloma patients using an administrative claims database.51 They found
overall the healthcare resource use (including number of patients with an admission, frequency
of prescription fills, frequency of office visits and laboratory services) and cost (total, hospital,
outpatient cost) was significantly higher in patients with CKD than patients without CKD.
The study by Candiril et al, was done in cancer patients with hematological malignancy
hospitalized with acute renal failure (ARF).52 They suggested that patients with hematologic
malignancy and ARF who require renal dialysis had the highest mean total cost ($44,619) compared
to patients with hematologic malignancy with ARF who do not require renal dialysis ($25,638) and
patients with hematologic malignancy who have no renal complications or do not require renal
dialysis ($13,947). Similarly, mean length of stay was highest for patients with hematologic
malignancy who had ARF and required renal dialysis (17.6 days) compared to patients with
hematologic malignancy who had ARF and did not require renal dialysis (12.2 days) and patients with
hematologic malignancy who have no renal complications or do not require renal dialysis (7.4 days).
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Chapter 3: GAPS IN LITERATURE
Six out of ten studies reviewed have been done in a single cancer center or a hospital with
electronic health records.44-49,52 The results of these studies could not be generalizable to the US
population. The healthcare utilization studies done by Bhowmik et al. and Qian et al. were done
with an administrative claims database.50,51 The results of these studies could not be
generalizable to individuals who are uninsured or individuals with only Medicare or Medicaid.
The healthcare utilization study done by Lahoti et al. was limited to one cancer center and did
not document utilization and expenditure well.49 The study by Li et al. was done at a population
level however it was limited to women above 65 years who were enrolled with Medicare and had
an early-stage breast cancer diagnosis.43 None of the studies evaluated the socioeconomic and
clinical risk factors of renal disease in cancer patients which are not limited to a single cancer
type.
Another gap is that none of the prior studies assessed health-related quality of life of this
patient population. Cancer patients with renal disease are vulnerable to adverse effects of cancer
therapies and this cohort of patients are usually excluded from clinical trials.53 Hence there is a
need to assess the health-related quality of life in this patient population.
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Chapter 4: RATIONALE
Except Li et al., none of the previous studies calculates the propensity to have a renal
disease in cancer patients at a population level.43 The study by Li et al. was limited to older
women with breast cancer patients at population level. This would be the first study at
population level which controlled for sociodemographic, economic and clinical factors. The
results of this study could be used by clinicians to incorporate care for individuals who have a
higher propensity to develop renal diseases. There have been studies assessing the expenditures
and utilization associated with renal disease in cancer patients in the US, however they were
limited to one cancer center or to patients who were commercially insured.49-51 Our study would
address this limitation by including patients with all types of insurance and uninsured individuals.
Our study would also include individuals with all cancer types, thus increasing generalizability.
There have been no studies which assess the health-related quality of life in cancer patients with
comorbid renal diseases. Previous studies have shown that patients with renal diseases have
worse health related quality of life, however this has not been proven in cancer patients. 54,55 Our
study uses a nationally representative database which is generalizable to the US population to
assess the health-related quality of life while controlling for sociodemographic, economic and
clinical factors.
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Chapter 5: CONCEPTUAL FRAMEWORK
We used the Andersen Health Behavioral Model which is widely accepted as a reliable
tool for the study of health services utilization.56 According to the Andersen model, as shown in
Figure 2, health service utilization is a sequential and conditional function of three sets of factors:
predisposing (demographic and social) factors, enabling (economic) factors, and need (clinical)
factors. Predisposing factors like age, race etc. reflects an individuals’ likelihood to use health
services. Enabling factors like income, employment and education are the resources that
facilitate access to services and need factors represent perceived and actual needs of health
service use, such as self-perceived health status and comorbid chronic conditions.
Figure 2: Andersen Health Behavior Model
Predisposing factors: sex, age, race, marital
status
Enabling factors: income, employment,
education
Need factors: - Type of
cancer, number of
comorbidities, Smoking
status, Hepatic disease,
Cardiovascular Disease

Outcomes: - Economic Outcome - Costs and
Healthcare utilization
- Health Outcome - Health
Related quality of life
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Chapter 6: SPECIFIC AIMS
AIM 1: To characterize the sociodemographic, economic and clinical characteristics of cancer
patients with renal diseases in the US civilian non-institutionalized population
AIM 2: To compare healthcare costs and utilization of cancer patients with renal diseases and
cancer patients without renal diseases in the US civilian non-institutionalized population
AIM 3: To compare health-related quality of life (HRQoL) of cancer patients with renal diseases
and cancer patients without renal diseases in the US civilian non-institutionalized population
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Chapter 7: SPECIFIC AIM 1
The first aim of our study was to examine the prevalence and predictors of renal disease
in cancer patients. We studied sociodemographic, economic and clinical characteristics of cancer
patients with renal diseases in the U.S. civilian non-institutionalized population. We hypothesized
that certain characteristics would differ significantly between the group of cancer patients with
renal disease and the group of cancer patients without renal disease. We also hypothesized that
certain characteristics would be significantly associated with likelihood of having a renal disease
in cancer patients.
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7.1 METHODS
STUDY DESIGN
This study was designed as a retrospective, cross-sectional study using Medical
Expenditure Panel Survey (MEPS).57 A sample of families and individuals across the United States
were interviewed for five rounds that covers two years. The data from the interviews was
collected and compiled into a publicly available dataset. We used data from the interviews
conducted from January 2009 to December 2018 for our study. We used the Household
Component (HC) of MEPS which provides data about demographics, health services, charges and
expenditures, etc. The files were downloaded and merged for this study to improve the sample
size.
STUDY SAMPLE
We identified individuals for our sample using the Medical Conditions files of MEPS.
Cancer patients from 2016 to 2018 were identified from ICD-10 codes (Table 1 of Appendix) and
patients were identified from 2009 to 2015 from ICD-9 codes (Table 2 of Appendix).58,59 Renal
disease diagnosis was identified from the Medical conditions files of 2016 to 2018 using ICD-10
codes from “N00” to “N39” (Table 3 of Appendix).60 ICD-9 codes from “580” to “599” (Table 4 of
Appendix) was used for renal disease diagnosis from the Medical Conditions files of 2009 to 2015.61
The Medical Condition files are event level files and hence after identifying the medical conditions
associated with renal disease or cancer, the files were transposed to person-level files in SAS
using PROC TRANSPOSE. After transposing, each person was identified as a patient with either
renal disease or cancer or both or none. Figure 3 shows the sample selection process. There were
241,247 individuals who responded to MEPS from 2009 to 2018 of which 11,441 patients were
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patients with cancer who were above the age of 18. Out of 11,441 cancer patients, 1,800
reported a diagnosis of renal disease and 9,641 did not report a diagnosis of renal disease.
Figure 3: Flow chart of sample size after inclusion and exclusion criteria for cancer patients
using Medical Expenditure Panel Survey (2009 – 2018)

MEPS Respondents (2009 – 2018)
N = 241,247

Cancer patients ≥ 18 years
N = 11,441

Patients with renal
disease diagnosis
N = 1,800

Patients without renal
disease diagnosis
N = 9,641

VARIABLES
Sociodemographic, economic information including sex, age, race, education, income,
employment, marital status and census region were obtained from the full year consolidated
files. Sex was directly used from MEPS which was coded as “Male” and “Female”. Age was a
continuous variable which was categorized as 18-44 years, 45 – 65 years, and above 65 years
which was consistent with previous study.75 Race was recoded as a new variable which indicated
“White”, “Black” and “Other races”. Other races included individuals who identified as American
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Indian, Asian, Native Hawaiian, Pacific Islander and Multiple Races. Marital status was recoded into
3 categories as “Married”, “Never Married” and “Widowed/Divorced/Separated”. Education was
recoded to a new variable which indicated “No School or less than High School”, “High School”
and “College and above”. Census region was used without recoding and labelled as “Northeast”,
“Midwest”, “South” and “West”. Income was a continuous variable in MEPS and was recoded
into more meaningful categories as “Low Income”, “Middle Income” and “High Income”. The
income variable was recoded based on a previous study where low income was defined as 100%
below the Federal Poverty Line (FPL). In 2021, the FPL for a single person was $12,880 and hence
low income was defined as an income less than $12,880.62 Middle income was defined as an
income between 100-400% of FPL, i.e., between $12,880 and $51,520 and high income was
defined an income above 400% of FPL, i.e., $51,520 and above. Insurance was used without change
and labelled as “Private”, “Public” and “Uninsured”. Employment was recoded into a new
variable which represented 2 categories “Employed” and “Unemployed”. Smoking status was
recoded into a new variable which represented “Smoker” and “Non-smoker”. Perceived health
status was recoded into a new variable which represented “Excellent”, “Very Good”, “Good”,
“Fair” and “Poor”. A new categorical variable was created to indicate the number of
comorbidities a cancer patient would have. Several chronic conditions such as diabetes, asthma,
arthritis, hypertension, hypercholesterolemia have been causally associated with an increased
risk of cancer and hence they were used to count the number of comorbidities.63-67 Categorical
variables which depicted whether a patient had a cardiovascular disease and hepatic disease
were also used in the analyses. These variables were created from ICD-9 and ICD-10 codes of the
Medical Condition files.
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Apart from the covariates, complex survey variables were also used in selected analyses
to have unbiased estimates which would account for the survey design and survey nonresponse.68 Complex survey variables included a pooled person-level weight, variance estimation
primary sampling unit and a sampling stratum required for variance estimation. Since this study
spans over 10 years, the pooled person-level weight was calculated by dividing the person-level
weight by 10.
The outcome variable for this aim was created from the medical conditions file as a
categorical variable which indicated whether the cancer patient had a renal disease diagnosis or
did not have a renal disease diagnosis.

STATISTICAL ANALYSES
A preliminary chi-square test was done in SAS using PROC SURVEYFREQ to assess the
significance of the sociodemographic, economic and clinical characteristics in cancer patients.
The chi square test was weighted using complex survey variables. The sample was summarized
using means and frequencies. A multivariable binomial logistic regression model using PROC
SURVEYLOGISTIC was used to estimate the likelihood of cancer patients to have a renal disease
and hence characterize the significant factors associated with the presence of renal disease in
the study sample. The model for multivariate binomial logistic regression was:
y = β0 + β1Age + β2Sex + β3Race + β4Marital Status + β5Census Region + β6Income + β7Insurance
Status + β8Employment Status + β9 Smoking Status + β10Health Status + β11Number of
comorbidities + β12Hepatic disease indicator + β13Cardiovascular disease indicator + ε0
y = Renal Disease Indicator
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The probability of having a renal disease was modelled. The variables were considered
statistically significant based on Type 3 analysis of effects. Results of the logistic regression was
summarized in Table 3 using odds ratio. The complex sampling design of the MEPS dataset was
considered by using variables which account for variance estimation strata, person level weights
and primary sampling unit. A significance level of 0.05 was used. SAS v9.4 was used for statistical
analyses and MS Excel was used for data visualization.
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7.2 RESULTS
The inclusion and exclusion criteria resulted in 11,441 cancer patients (weighted
frequency = 13,858,510). Out of this, 1,800 patients had a renal disease diagnosis (weighted
frequency = 2,183,534). Table 2 shows the distribution of sociodemographic, economic and
clinical characteristics of these cancer patients.
Figure 4: Prevalence of renal disease in cancer patients in non-institutionalized US population
from 2009 - 2018

WEIGHTED POPULATION
Renal disease present

Renal disease absent

Renal disease
absent
11,674,976
84%

Renal disease
present
2,183,534
16%

Table 2: Distribution of sociodemographic, economic and clinical factors in cancer patients in
the US from 2009 - 2018
Sociodemographic,
Economic and
Clinical Factors
Overall, n (%)
Agea (years) mean (S.D)

Cancer patients with
Renal disease
Freq (%)
1800 (15.73)

p-value*

< 0.0001
66.20 (14.76)

Age groups
18 - 44 years
45 – 64 years
65+ years
Missing
Sex
Male
Female
Missing

Cancer patients
without Renal disease
Freq (%)
9641 (84.27)
61.05 (15.85)

< 0.001
182 (10.11)
510 (28.33)
1108 (61.56)
0

1588 (16.47)
3554 (36.86)
4499 (46.67)
0

697 (38.72)
1103 (61.28)
0

4198 (43.54)
5443 (56.46)
0

0.0049
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Race
White
Black
Others
Missing
Marital Status
Married
Widowed/Divorced/
Separated
Never Married
Missing
Education
No School or less than HS
High School
College or above
Missing
Census Region
Northeast
Midwest
South
West
Missing
Incomea (USD) mean

0.0411
1506 (83.67)
212 (11.78)
82 (4.56)
0

< 0.0001
951 (52.83)
678 (37.67)

5584 (57.91)
2845 (29.51)

171 (9.50)
0

1212 (12.57)
0
0.2239

286 (15.89)
697 (38.72)
804 (44.67)
13 (0.72)

1358 (14.09)
3746 (38.85)
4461 (46.27)
76 (0.79)

270 (15.00)
408 (22.67)
721 (40.06)
400 (22.22)
1 (0.06)

1737 (18.02)
2107 (21.85)
3502 (36.32)
2284 (23.69)
11 (0.11)

0.0031

< 0.0001
39952.07

Incomeb
Low
Middle
High
Missing
Insurance
Private
Public
Uninsured
Missing
Employment status
Employed
Unemployed
Missing
Smoking status
Smoker
Non-smoker
Missing
Health Status
Excellent
Very Good
Good

7828 (81.19)
1282 (13.30)
531 (5.51)
0

46530.11
< 0.0001

362 (20.11)
899 (49.94)
478 (26.56)
61 (3.39)

1544 (16.01)
4736 (49.12)
2943 (30.53)
418 (4.34)

1067 (59.28)
688 (38.22)
45 (2.50)
0

6222 (64.54)
3012 (31.24)
407 (4.22)
0

< 0.0001

< 0.0001
557 (30.94)
1243 (69.06)
0

4477 (46.44)
5097 (52.87)
67 (0.69)
0.0028

202 (11.22)
1229 (68.28)
369 (20.50)

1305 (13.54)
6199 (64.30)
2137 (22.17)
< 0.0001

292 (16.22)
491 (27.28)
528 (29.33)

2322 (24.08)
3054 (31.68)
2604 (27.01)
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Fair
Poor
Missing
Number of comorbidities
0
1
2
3
4+
Missing
Hepatic Disease
Absent
Present
Missing
Cardiovascular Disease
Absent
Present
Missing

336 (18.67)
153 (8.50)
0

1027 (12.52)
408 (4.23)
46 (0.48)

191 (10.67)
279 (15.50)
454 (25.22)
474 (26.33)
402 (22.28)
0

1953 (20.26)
2175 (22.56)
2352 (24.40)
2021 (20.96)
1140 (11.82)
0

1762 (97.89)
38 (2.11)
0

9555 (99.11)
86 (0.89)
0

533 (29.61)
1267 (70.39)
0

4493 (46.60)
5148 (53.40)
0

< 0.0001

< 0.0001

< 0.0001

P-values are obtained from chi-square test
a - p-values obtained from Satterthwaite test
b - Income groups: Low income – less than $12,880; Middle income - between $12,880 and
$51,520; High income – above $51,520
HS – High School

Almost 2/3rd of the patients with renal disease were older cancer patients. Majority of the
population identified as whites in both the groups. Nearly half of the population in both the
groups were married. Majority of the cancer population in both the groups had a high school
education. Almost half of the cancer population belonged to the middle-income category and
more than half of the cancer population in both the groups had a private insurance. There were
more unemployed cancer patients with renal disease than cancer patients without renal disease
(69.06% vs 52.87%). Unadjusted analyses from the chi-square test and Satterthwaite test shown
in Table 2 showed that at significance value of 0.05, all the variables differed significantly
between the two groups except education (p = 0.2239).
The significant variables were included in the binomial logistic model to calculate the odds
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ratio. The results from the binomial multivariate logistic regression are shown in Table 3 below.
The results show that that in the presence of all other variables, only sex, census region,
employment status, smoking status, health status, number of comorbid diseases, cardiovascular
and hepatic diseases had significant odds ratio. We found that compared to females, males were
30% less likely to have renal diseases (p<0.0001). Overall census region significantly predicts
likelihood of having a renal disease in cancer patients (p=0.0062). The odds of having a renal
disease were 30% lower in cancer patients living in Northeast than cancer patients living in
Midwest. We also found that compared to unemployed, cancer patients who were employed
were almost 30% less likely to have renal diseases (p=0.0010). Smokers were almost 40% less
likely to have renal disease than non-smokers (p=0.0001). Overall health status significantly
predicts likelihood of having a renal disease in cancer patients (p=0.0029). Compared to cancer
patients who reported having a poor health status, cancer patients who reported having an
excellent health status were almost 40% less likely to have renal diseases. Overall number of
comorbidities significantly predicts likelihood of having a renal disease in cancer patients
(p=0.0001). Cancer patients with 4 or more comorbidities were almost 79% more likely to have a
renal disease than cancer patients with no comorbidities. Cancer patients with hepatic disease
were almost 3 times more likely to have a renal disease than cancer patients who did not have a
hepatic disease (p<0.0001). Cancer patients with cardiovascular disease were 27% more likely to
have a renal disease than cancer patients who did not have a CVD (p=0.00231).
Table 3: Sociodemographic, Economic and Clinical Factors associated with renal diseases in
cancer patients in the United States from 2009 - 2018
Covariates
Odds Ratio
95% Confidence Intervals
P-value
Upper limit
Lower limit
Age
0.0536
18-44 years
0.985
0.749
1.295
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45-64 years
65+ years

0.817
REFERENCE
Sex**
Male
0.692
Female
REFERENCE
Race
Black
0.856
Others
1.025
White
REFERENCE
Marital status
Never married
0.973
Widowed/Divorced/Separated
1.098
Married
REFERENCE
Census Region**
South
1.001
West
0.836
Northeast
0.712
Midwest
REFERENCE
Income
Low
0.905
Middle
0.929
High
REFERENCE
Insurance
Uninsured
0.827
Public
0.974
Private
REFERENCE
Employment status**
Employed
0.680
Unemployed
REFERENCE
Smoking status**
Smoker
0.634
Non-smoker
REFERENCE
Health Status**
Excellent
0.593
Very Good
0.644
Good
0.72
Fair
0.866
Poor
REFERENCE
Number of comorbidities**
1
0.978
2
1.276
3
1.437
4+
1.786
0
REFERENCE
Hepatic Disease**
Present
2.974

0.673
-

0.991
< 0.0001

0.587

0.817
0.2420

0.712
0.736
-

1.029
1.427
0.4083

0.744
0.945
-

1.272
1.276
0.0062

0.852
0.690
0.570
-

1.177
1.012
0.889
-

0.704
0.785
-

1.163
1.099
-

0.468
0.821
-

1.459
1.155
-

0.560
-

0.824
-

0.504
-

0.797
-

0.6622

0.9024

0.0010
<0.0001
0.0029
0.413
0.467
0.527
0.6
-

0.851
0.889
0.984
1.25
0.0001

0.737
0.916
1.025
1.254
-

1.299
1.777
2.015
2.543
< 0.0001

1.727

5.12
37

Absent

REFERENCE
Cardiovascular Disease**
Present
1.277
1.034
Absent
REFERENCE
** statistically significant at p=0.05 based on Type 3 test

0.00231
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7.3 DISCUSSIONS
Our study examined the characteristics associated with renal disease in cancer patients.
To our knowledge, this is the first population-based study in cancer patients which was not
limited to one cancer type. We found that certain characteristics were significantly associated
with renal disease. One of our findings was that males were less likely to have renal disease than
females. This could be because pregnancy is a risk factor for renal disease. 31 Women are also
more likely to have a urinary tract infection which is a risk factor for renal disease. 69-70 We found
that cancer patients who are older (65+ years) are more likely to have a renal disease than cancer
patients who are between 18 – 44 years and 45 - 64 years, although this finding was not
statistically significant (p = 0.0536). These were similar to the results reported in the study by
Lahoti et al. in patients with acute myelogenous leukemia (AML) or high-risk myelodysplastic
syndrome (OR = 1.8, p = 0.012).44
Lifestyle risk factors such as smoking have been associated with a risk of CKD and up to 9fold increased risk of cancer.71,72 However our study found smoking as a protective factor where
cancer patients who were smokers were 40% less likely to have a renal disease than cancer
patients who were non-smokers. As shown in Table 2, almost 20-22% of the data for smoking
status was missing and hence this association could be biased. This association could be studied
further in a longitudinal data where causal relationship is established. A meta-analysis in general
population found that individuals with liver disease were almost twice more likely to have CKD
(OR = 2.12).73 In our study, cancer patients with liver diseases were almost 3 times more likely to
have a renal disease (OR = 2.974). Our study also confirmed the association of renal disease and
CVD in cancer patients (OR = 1.277). This association has been observed in the general population
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by Foley et al.74 This might be due to shared risk factors such as age between renal disease and
CVD.
There are several limitations in this study. Firstly, this study is a cross sectional study and
hence causality cannot be inferred. The associations that have been found between the
predictors and outcomes could not be proven true over a longitudinal duration. Secondly, since
MEPS is a patient reported survey, there may be some self-reporting bias, where individuals tend
to report inaccurate or false information.75 Thirdly there may also be recall bias where
participants do not remember previous events or experiences accurately or omit details.75
Fourthly, the design of data collection is such that one member of the household answers the
survey for all the other members of the household which may lead to errors.75 We could not
exclude individuals with a prior renal diagnosis because of missing data for age of diagnosis of
cancer and renal disease. We have assumed that all the patients who were diagnosed with renal
disease were treated for it. We did not establish an association of cancer therapies and adjuvant
drugs to renal disease in cancer patients and this could be a potential hypothesis for further
research. Finally, the prevalence of individuals diagnosed with renal disease and cancer is
depicted in the study and could not account for individuals who have cancer and renal disease
but are undiagnosed.
Despite the limitations mentioned above, our study still has some implications. Our study
determines the risk factors associated with renal disease in cancer patients in a nationally
representative sample. Using a nationally representative sample increases generalizability of our
results. Our study found that certain factors such as being female, being older, or having a
comorbid cardiovascular disease or hepatic diseases increases the propensity to develop renal
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disease in cancer patients. Our study also proves the association of renal disease and cancer
development. Given the link between renal disease and cancer development, the aim of this
study highlights the importance of multidisciplinary collaboration between oncologist and
nephrologist to predict and prevent renal diseases. The results of our study could also inform
clinicians to incorporate care and heighten monitoring for patients who have more propensity to
develop

renal

disease.

41

Chapter 8: SPECIFIC AIM 2
The second aim of our study was to compare healthcare expenditure and utilization of cancer
patients with renal diseases and cancer patients without renal diseases in the U.S. civilian noninstitutionalized population. We hypothesized that cancer patients with renal diseases had
significantly higher healthcare expenditure and utilization than cancer patients without renal
diseases.

8.1 METHODS
STUDY DESIGN
This study was designed as a retrospective, cross-sectional study using Medical
Expenditure Panel Survey (MEPS).57 A sample of families and individuals across the United States
were interviewed for five rounds that covers two years. The data from the interviews was
collected and compiled into a publicly available dataset. We used data from the interviews
conducted from January 2009 to December 2018 for our study. We used the Household
Component (HC) of MEPS which provides data about demographics, health services, charges and
expenditures, etc. The files were downloaded and merged for this study to improve the sample
size.
STUDY SAMPLE
We identified individuals for our sample using the Medical Conditions files of MEPS.
Cancer patients from 2016 to 2018 were identified from ICD-10 codes (Table 1 of Appendix) and
patients were identified from 2009 to 2015 from ICD-9 codes (Table 2 of Appendix).58,59 Renal
disease diagnosis was identified from the Medical conditions files of 2016 to 2018 using ICD-10
codes from “N00” to “N39” (Table 3 of Appendix).60 ICD-9 codes from “580” to “599” (Table 4 of
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Appendix) was used for renal disease diagnosis from the Medical Conditions files of 2009 to 2015.61
The Medical Condition files are event level files and hence after identifying the medical conditions
associated with renal disease or cancer, the files were transposed to person-level files in SAS
using PROC TRANSPOSE. After transposing, each person was identified as a patient with either
renal disease or cancer or both or none. There were 241,247 individuals who responded to MEPS
from 2009 to 2018 of which 11,441 were patients with cancer who were above the age of 18.
Out of 11,441 cancer patients, 1,800 reported a diagnosis of renal disease (“Renal disease group”)
and 9,641 did not report renal disease diagnosis (“Control group”). To reduce selection bias, the
“Renal disease” group was matched in a 1:1 ratio with the Control group using propensity score
matching (PSM). Propensity score matching is a 2-step process where the first step is to calculate
the probability of a cancer patient being diagnosed with renal disease. A propensity score was
calculated using multiple logistic regression with renal disease indicator, sex, age, region, income,
race and marital status as matching variables, where income and age were used as continuous
variables. In the second step the Renal disease group and the Control group were matched using
a greedy matching technique with replacement. The quality of match was assessed using
standardized differences, where a standardized difference of less than 0.1 was considered a good
match. Variance ratio, the ratio of treatment variance and control variance was also used to
compare the quality of match. A ratio closer to 1 was considered a good match.
VARIABLES
Sociodemographic, economic information including sex, age, race, education, income,
employment, marital status and census region were obtained from the full year consolidated
files. Sex was directly used from MEPS which was coded as “Male” and “Female”. Age was a
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continuous variable which was categorized as 18-44 years, 45 – 65 years, and above 65 years
which was consistent with previous study.75 Race was recoded as a new variable which indicated
“White”, “Black” and “Other races”. Other races included individuals who identified as American
Indian, Asian, Native Hawaiian, Pacific Islander and Multiple Races. Marital status was recoded into
3 categories as “Married”, “Never Married” and “Widowed/Divorced/Separated”. Education was
recoded to a new variable which indicated “No School or less than High School”, “High School”
and “College and above”. Census region was used without recoding and labelled as “Northeast”,
“Midwest”, “South” and “West”. Income was a continuous variable in MEPS and was recoded
into more meaningful categories as “Low Income”, “Middle Income” and “High Income”. The
income variable was recoded based on a previous study where low income was defined as 100%
below the Federal Poverty Line (FPL). In 2021, the FPL for a single person was $12,880 and hence
low income was defined as an income less than $12,880.62 Middle income was defined as an
income between 100-400% of FPL, i.e., between $12,880 and $51,520 and high income was
defined an income above 400% of FPL, i.e., $51,520 and above. Insurance was used without change
and labelled as “Private”, “Public” and “Uninsured”. Employment was recoded into a new
variable which represented 2 categories “Employed” and “Unemployed”. Smoking status was
recoded into a new variable which represented “Smoker” and “Non-smoker”. Perceived health
status was recoded into a new variable which represented “Excellent”, “Very Good”, “Good”,
“Fair” and “Poor”. A new categorical variable was created to indicate the number of
comorbidities a cancer patient would have. Several chronic conditions such as diabetes, asthma,
arthritis, hypertension, hypercholesterolemia have been causally associated with an increased
risk of cancer and hence they were used to count the number of comorbidities.63-67 Categorical
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variables which depicted whether a patient had a cardiovascular disease and hepatic disease
were also used in the analyses. These variables were created from ICD-9 and ICD-10 codes of the
Medical Condition files. A categorical variable was created which indicated whether the cancer
patient had a renal disease diagnosis or did not have a renal disease diagnosiswas used as the main
independent variable.
The outcome variables included healthcare utilization variables and cost variables. The
utilization variable included the number of office-based visits to the physician and number of
prescribed medicines which included refills. The healthcare expenditure variables included outof-pocket cost associated with the office-based visits to the physician, amount paid for an officebased visit to the physician from all the sources of payments, out-of-pocket cost associated with
prescribed medicines including refills and amount paid for prescribed medicines including refills
from all sources of payments. We also included total out of pocket expenditure which was
calculated as a sum of out-of-pocket cost associated with inpatient visits, outpatient visits,
emergency visits, office-based visits to a physician, and out-of-pocket associated with prescribed
medicines (including refills). Total expenditure from all sources of payment was calculated as a sum
of expenditure associated with inpatient visits, outpatient visits, emergency visits, office-based
visits to a physician, and expenditure associated with prescribed medicines (including refills). All
sources of payment included payments from out of pocket, Medicare, Medicaid, private
insurance, Veteran’s administration, TRICARE, other federal sources, other state and local
sources, workers’ compensation, other private, other public, and other unclassified sources.
STATISTICAL ANALYSES
The unadjusted mean expenditure for both groups were compared using t-tests.
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Statistical differences for count outcomes between cancer patients with renal disease and
without renal disease were analyzed using the Wilcoxon Rank Sum Test. Due to skewed data,
traditional ordinary least squares (OLS) was not used for modelling the cost outcome. Even
though the log-transformed OLS would account for the skewed data, the interpretation of
estimates would be difficult. Therefore, we used a generalized linear model using the log link
function to model cost outcomes. We used the traditional Poisson regression for modelling the
count outcomes and assumed that the means and variances are equal. The model was built using
PROC GLM as following:
y = β0 + β1Age + β2Sex + β3Race + β4Marital Status + β5Census Region + β6Income + β7Insurance
Status + β8Employment Status + β9Smoking Status + β10Health Status + β11Number of
comorbidities + β12Renal Disease Indicator + β13Hepatic disease indicator + β14Cardiovascular
disease indicator + ε0
y = # of office-based visits / # of prescribed medicines including refills / out-of-pocket cost
associated with office-based visits / out-of-pocket cost associated with prescribed medicines
(including refills) / out-of-pocket cost associated with total medical costs / amount paid by all
sources of payment associated with office-based visits / amount paid by all sources of payment
associated with prescribed medicines (including refills) / amount paid by all sources of payment
associated with total medical costs
A significance level of 0.05 was used and SAS v9.4 was used for statistical analyses. MS Excel was
used to plot the graphs.
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8.3 RESULTS
There were 1,736 patients in the treatment group (patients with renal disease) and 9,221
patients in the control group (patients without renal disease) before matching. The sample
characteristics before matching and after matching are compared in Table 6 and the distribution
of propensity score before and after matching is shown below in Figure 5 and 6. Before matching,
the mean age for renal disease group was 66.20 years and 61.05 years for control group. The
renal disease group had a higher proportion of individuals who identified as males (44% vs 39%),
white (84% vs 81%), widowed/divorced/separated (38% vs 30%) and living in South (40% vs 36%)
than control group. The mean income was lower in the renal disease group than the control group
($39,998 vs $46,610). After matching, there were 1,736 patients in the treatment group and
1,736 patients in the control group. The magnitude of the difference between the treatment and
control group decreased after matching. The mean and standard deviation of the propensity
scores of the two groups as shown in Table 4 were equal after matching indicating less variance
and more balance between the two groups. As shown in Table 5, the absolute value of
standardized difference of propensity scores and matching variables was closer to 0 after
matching indicating less variance between the two groups. After matching, the ratio of variance
of treatment group to control group (variance ratio) was closer to 1 indicating equal variance was
achieved in both the groups after matching. After matching, the mean age of renal disease group
was 66.60 years and 66.62 years for control group. The renal disease group had an almost equal
proportion of individuals who identified as females (61% vs 61%), white (84% vs 84%), married
(52% vs 53%) and living in South (40% vs 39%) than control group. The mean income was also
almost equal ($40,039 vs $39,623) in both the groups.
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Table 4: Distribution of propensity scores of both the groups before and after matching
Treated (Renal = YES)
Control (Renal = NO)
Before Matching After Matching Before Matching After Matching
Sample size
1736
1736
9221
1736
Mean
0.1774
0.1774
0.1549
0.1774
Standard Deviation 0.0544
0.0544
0.0553
0.0544
Minimum
0.0497
0.0497
0.0307
0.0495
Maximum
0.3483
0.3483
0.3627
0.3627

Table 5: Metrics to compare quality of match
Variable
Observations
Mean
Standard Standardized
Difference Deviation Difference
Propensity Score Before Matching
0.18
0.42
0.43147
After Matching
-0.00
-0.00007
Age
Before Matching
5.11
15.13
0.33772
After Matching
-0.02
-0.00141
Income
Before Matching -6578.16 39711.69
-0.16565
After Matching
416.66
0.01049
Sex
Before Matching
0.05
0.49
0.10690
After Matching
-0.00
-0.00585

Variance
Ratio
0.7936
0.9997
0.8667
1.0939
0.6772
1.0677
0.9648
1.0027

Figure 5: Distribution of propensity scores of cancer patients with renal disease and without
renal diseases before matching

48

Figure 6: Distribution of propensity scores of cancer patients with renal disease and without
renal diseases after matching

Table 6: Sample characteristics of cancer patients with renal disease and without renal
disease before and after matching
Variables
Before Matching
After Matching
RENAL DISEASE
PRESENT
ABSENT
PRESENT
ABSENT
Age (mean, SD)
66.20 (14.76) 61.05 (15.85) 66.60 (14.56)
66.62 (13.94)
Sex
Male
697 (43.56) 4200 (38.72) 679 (39.11)
674 (38.82)
Female
5441 (56.44) 1103 (61.28) 1057 (60.89)
1062 (61.18)
Race
White
1506 (83.67) 7828 (81.19) 1453 (83.70)
1466 (84.45)
Black
212 (11.78) 1282 (13.30) 203 (11.69)
199 (11.46)
Others
82 (4.55)
531 (5.52)
80 (4.61)
71 (4.09)
Income (Median, SD)
39998.01
46610.82
40039.35
39622.69
(35671.33)
(43362.73)
(35686.30)
(34536.24)
Marital Status
Married
951 (52.83) 5584 (57.92) 911 (52.48)
928 (53.46)
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Widowed/Divorced/Separated
Never Married
Region
Northeast
Midwest
South
West

678 (37.67)
171 (9.50)

2845 (29.51)
1212 (12.57)

661 (38.08)
164 (9.45)

655 (37.73)
153 (8.81)

269 (14.94)
407 (22.61)
721 (40.06)
399 (22.17)

1740 (18.05)
2109 (21.88)
3506 (36.37)
2284 (23.69)

259 (14.92)
400 (23.04)
690 (39.75)
387 (22.29)

289 (16.65)
393 (22.64)
676 (38.94)
378 (21.77)

UNADJUSTED RESOURCE UTILIZATION AND COSTS
The sample included 1,736 patients in each group of patients with renal disease and
without renal disease. As shown in Table 7, respondents with renal disease had higher unadjusted
mean out-of-pocket cost associated with office-based provider visits ($507.02 vs $464.87,
p=0.3963), prescribed medicines (including refills) ($1203.21 vs $867.28, p<0.0001) and total
medical costs ($2041.37 vs $1695.56, p=0.0155) compared to patients without renal disease.
Unadjusted mean cost from all sources of payment associated with office-based provider visits
($7069.39 vs $5165.08, p<0.0001), prescribed medicines (including refills) ($9554.65 vs
$6007.22, p<0.0001) and total medical costs ($33185.46 vs $21133.39, p<0.0001) compared to
patients without renal disease. Except for out-of-pocket costs associated with office-based
provider visits (p=0.3963), cancer patients with renal disease had a significantly higher mean
costs than cancer patients without renal disease. The results for unadjusted utilization measures
for cancer patients are shown in Table 8. The results show a higher median office-based visits to
provider (17 vs 12, p<0.0001) and higher median prescriptions filled (including refills) (53 vs 31,
p<0.0001) for cancer patients with renal disease than cancer patients without renal disease.
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Table 7: Unadjusted mean cost estimates for cancer patients with renal disease and without renal disease in propensity matched
groups from MEPS (2009 – 2018)
Expenditure measure ($)
Cancer Patients with renal disease
Patients without renal disease
P -value

Office-based

Mean ($)

SD

95% CI

Mean ($)

Out-of-pocket

507.02

1153.04

452.75 -561.30

464.87

All sources of

7069.39 11909.30

SD

95% CI

1718.52 383.99 – 545.78 0.3963

visits

payment**

Prescribed

Out-of-pocket**

5165.08 13475.27

7630.00

1203.21

2431.66

medicines

1088.74 -

4530.75 –

<0.0001

5799.41

867.28

2535.92

747.91- 986.66 <0.0001

1317.68
All sources of

9554.65 21788.23

payment**
Total medical

6508.78 –

Out-of-pocket**

8529.00 –

6007.22 20690.31

10580.30
2041.37

3234.82

costs

1889.10 -

payment**

33185.46 50679.29

30799.81 –
35571.11

Abbreviation used: SD = Standard deviation; CI = Confidence interval; **significant at p = 0.05

<0.0001

6981.19
1695.56

4994.07

2193.65

All sources of

5033.26 –

1460.47 –

0.0155

1930.65

21133.39 44021.41

19061.15 –
3205.63

<0.0001

Table 8: Unadjusted utilization estimates for cancer patients with renal disease and without
renal disease in propensity matched groups from MEPS (2009 – 2018)
Utilization
Renal
Median
Range
Mean
SD
95% CI
P-value
measure (#)

disease

Office

Present

17.00

based visits
to provider

0.00 –

26.56

29.43

354.00
Absent

12.00

0.00 –

Present

53.00

fills

17.48

21.10

Absent

31.00

0.00 –
720.00

16.48 –
18.47

85.45

100.72

836.00

including
refills

0.00 –

< 0.0001

27.95

326.00
Prescription

25.18 –

80.71 –

< 0.0001

90.19
55.01

72.11

51.62 –
58.40

Abbreviation used: SD = Standard deviation; CI = Confidence interval; p-value obtained from
Wilcoxon signed rank sum test
ADJUSTED RESOURCE UTILIZATION AND COSTS
The sample for adjusted analyses included 1,385 cancer patients with renal disease and
1,342 cancer patients without renal disease. The results of the generalized linear model, after
including only non-zero costs in matched groups and adjusting for covariates are shown in Table
9. Similar to unadjusted results, individuals with renal disease had higher costs associated with
office-based provider visits, prescribed medicines (including refills) and total medical costs
compared to patients without renal disease. As shown in Table 10, respondents with renal
disease had higher adjusted mean out-of-pocket cost associated with office-based provider visits
($711.79 vs $670.70, p<0.0001), prescribed medicines (including refills) ($1370.24 vs $1022.66,
p<0.0001) and total medical costs ($2274.67 vs $1907.74, p<0.0001) compared to patients
without renal disease. Adjusted mean cost from all sources of payment associated with officebased provider visits ($7881.35 vs $5683.24, p<0.0001), prescribed medicines (including refills)
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($11068.02 vs $6764.57, p<0.0001) and total medical costs ($37283.40 vs $22402.58, p<0.0001)
compared to patients without renal disease. The results for adjusted utilization measures for
cancer patients are shown in Table 9. The results show a higher mean office-based visits to
provider (29.60 vs 19.94, p<0.0001) and higher mean prescriptions filled (including refills) (96.75
vs 63.32, p< 0.0001) for cancer patients with renal disease than cancer patients without renal
disease. Median office-based visits to provider was higher for cancer patients with renal disease
than cancer patients without renal disease (30.50 vs 20.61); this difference represents a 50%
increase (p < 0.0001). Similarly, median prescriptions filled including refill was increased by
almost 57% for cancer patients with renal disease than cancer patients without renal disease.
Similar to unadjusted results, we see a patten of higher mean and median visits to office-based
provider and prescription fills for patients with renal disease compared to patients without renal
disease.
Table 9: Adjusted utilization estimates for cancer patients with renal disease and without
renal disease in propensity matched groups from MEPS (2009 – 2018)
Utilization
Renal
Median
Range
Mean
SD
95% CI
P-value
measure (#)

disease

Office based Present

30.50

7.89 – 77.12

29.60

10.38

visits to
provider

29.05 –

< 0.0001

30.15
Absent

20.61

5.99 – 37.51

19.94

7.03

19.57 –
20.32

Prescription

Present

88.83

fills
including
refills

15.96 –

96.75

56.76

412.25
Absent

56.74

12.68 –

93.76 –

< 0.0001

99.75
63.32

38.40

198.41

61.27 –
65.38

Abbreviation used: SD = Standard deviation; CI = Confidence interval;
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Figure 7: Adjusted number of prescriptions filled including refills for cancer patients with renal
disease and without renal disease in propensity matched groups from MEPS (2009 – 2018)

Figure 8: Adjusted number of office-based visits to a physician for cancer patients with renal
disease and without renal disease in propensity matched groups from MEPS (2009 – 2018)
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Table 10: Adjusted mean cost estimates for cancer patients with renal disease and without renal disease in propensity matched
groups from MEPS (2009 – 2018)
Expenditure measure ($)
Patients with renal disease
Patients without renal disease
P-value
Mean ($) SD
95% CI
Mean ($) SD
95% CI
Office-based
Out-of-pocket
711.79
204.83
700.98 – 722.60 670.70
184.07
660.85 – 680.56 <0.0001
visits

All sources
payment

Prescribed
medicines

Out-of-pocket

All sources
payment

Total medical
costs

of 7881.35

1370.24

2728.287 7737.38 –
8025.32

5683.24

1996.12

5576.34 –
5790.13

<0.0001

645.57

1336.17 –
1404.30

1022.66

506.92

995.52 –
1049.81

<0.0001

10658.21 –
11477.84

6764.57

4161.37

6541.72 –
6987.41

<0.0001

2236.67 –
2312.67

1907.74

608.18

1875.17 –
1940.31

<0.0001

22402.58 10642.39 21832.6722972.48

<0.0001

of 11068.02 7766.29

Out-of-pocket

2274.67

720.16

All sources of
payment

37283.40 17482.95 36360.85 –
38205.95

Abbreviation used: SD = Standard deviation; CI = Confidence interval;

8.4 DISSCUSSION
The major finding of this aim was that mean unadjusted costs and utilization were higher for
cancer patients with renal disease than cancer patients without renal disease. The sample used
in this aim were MEPS respondents who were diagnosed with cancer and above the age of 18.
Previous studies have shown that kidney damage represented by an increase in serum creatinine
level has been correlated with increased hospital cost in cancer patients admitted to the ICU.49
Our study showed similar results, kidney damage in cancer patients was associated with higher
mean out-of-pocket cost for office-based visits ($41), prescribed medicines ($348) and total
medical cost ($366.93). Apart from out-of-pocket costs, kidney damage was also associated with
higher costs from all sources of payment for office-based visits ($2,188), prescribed medicines
($4,303) and total medical costs ($14,881). Similar results were found by Bhowmik et al. in
patients with multiple myeloma using claims database.51 They found that patients with CKD had
higher frequency of physician office visits (1.2 vs 0.5), prescription fills (74.6 vs 57.9) than patients
without CKD. A study by Qian et al. had similar results in patients with bone metastases from
solid tumor.50 They found that patients with renal impairment had higher physician’s visits (22.9
vs 18.8), outpatient pharmacy visits (49.2 vs 40.8) and outpatient pharmacy costs ($10,315 vs
$7,718).
There were many limitations for this study. Firstly, to account for the shape of the cost
and utilization outcomes, we used generalized linear model and Poisson regression model. These
models could not account for complex sampling weights which are used to produce estimates of
nationally representative samples. Hence the results of this aim are generalizable only to the
participants of MEPS and not the US population. Secondly, we assumed that the mean and
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variances of the utilization variables are equal. Hence, we could not control for overdispersion in
the Poisson regression. Thirdly, we did a propensity score matching to account for selection bias
and confounding; however, differences between the cohorts might still exist for unobservable
characteristics (e.g., stages of cancer, patient preferences). Indirect costs such as loss of
productivity for the patient or the caregiver was not accounted for and thus the economic burden
estimated might be underestimated.
Despite the limitations mentioned above, our study still has some implications. This study
was the first in cancer patients which was not limited to one cancer type. Unlike the previous
studies by Bhowmik et al. and Qian et al., the expenditure was accounted for individuals with
public and private insurance as well as uninsured.50,51 Our study estimates the mean expenditure
for cancer patients with renal disease. This could be used by payers to estimate savings that can
potentially accrue if care and preventive measures are incorporated in cancer patients who have
a propensity to develop renal disease.
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CHAPTER 9: SPECIFIC AIM 3
The third aim of our study was to compare health-related quality of life (HRQoL) of cancer
patients with renal diseases and cancer patients without renal diseases in the U.S. civilian noninstitutionalized population. We hypothesized that the cancer patients with renal disease will
have lower mean PCS and MCS scores than cancer patients without renal disease. A lower score
indicates worse HRQoL.

9.1 METHODS
STUDY DESIGN
This study was designed as a retrospective, cross-sectional study using Medical
Expenditure Panel Survey (MEPS).57 A sample of families and individuals across the United States
were interviewed for five rounds that covers two years. The data from the interviews was
collected and compiled into a publicly available dataset. We used data from the interviews
conducted from January 2009 to December 2018 for our study. We used the Household
Component (HC) of MEPS which provides data about demographics, health services, charges and
expenditures, etc. The files were downloaded and merged for this study to improve the sample
size.
STUDY SAMPLE
We identified individuals for our sample using the Medical Conditions files of MEPS.
Cancer patients from 2016 to 2018 were identified from ICD-10 codes (Table 1 of Appendix) and
patients were identified from 2009 to 2015 from ICD-9 codes (Table 2 of Appendix).58,59 Renal
disease diagnosis was identified from the Medical conditions files of 2016 to 2018 using ICD-10
codes from “N00” to “N39” (Table 3 of Appendix).60 ICD-9 codes from “580” to “599” (Table 4 of
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Appendix) was used for renal disease diagnosis from the Medical Conditions files of 2009 to 2015.61
The Medical Condition files are event level files and hence after identifying the medical conditions
associated with renal disease or cancer, the files were transposed to person-level files in SAS
using PROC TRANSPOSE. After transposing, each person was identified as a patient with either
renal disease or cancer or both or none. Figure 3 shows the sample selection process. There were
241,247 individuals who responded to MEPS from 2009 to 2018 of which 11,441 patients were
patients with cancer who were above the age of 18. Out of 11,441 cancer patients, 1,800
reported a diagnosis of renal disease and 9,641 did not report a diagnosis of renal disease.
VARIABLES
Sociodemographic, economic information including sex, age, race, education, income,
employment, marital status and census region were obtained from the full year consolidated
files. Sex was directly used from MEPS which was coded as “Male” and “Female”. Age was a
continuous variable which was categorized as 18-44 years, 45 – 65 years, and above 65 years
which was consistent with previous study.75 Race was recoded as a new variable which indicated
“White”, “Black” and “Other races”. Other races included individuals who identified as American
Indian, Asian, Native Hawaiian, Pacific Islander and Multiple Races. Marital status was recoded into
3 categories as “Married”, “Never Married” and “Widowed/Divorced/Separated”. Education was
recoded to a new variable which indicated “No School or less than High School”, “High School”
and “College and above”. Census region was used without recoding and labelled as “Northeast”,
“Midwest”, “South” and “West”. Income was a continuous variable in MEPS and was recoded
into more meaningful categories as “Low Income”, “Middle Income” and “High Income”. The
income variable was recoded based on a previous study where low income was defined as 100%
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below the Federal Poverty Line (FPL). In 2021, the FPL for a single person was $12,880 and hence
low income was defined as an income less than $12,880.62 Middle income was defined as an
income between 100-400% of FPL, i.e., between $12,880 and $51,520 and high income was
defined an income above 400% of FPL, i.e., $51,520 and above. Insurance was used without change
and labelled as “Private”, “Public” and “Uninsured”. Employment was recoded into a new
variable which represented 2 categories “Employed” and “Unemployed”. Smoking status was
recoded into a new variable which represented “Smoker” and “Non-smoker”. Perceived health
status was recoded into a new variable which represented “Excellent”, “Very Good”, “Good”,
“Fair” and “Poor”. A new categorical variable was created to indicate the number of
comorbidities a cancer patient would have. Several chronic conditions such as diabetes, asthma,
arthritis, hypertension, hypercholesterolemia have been causally associated with an increased
risk of cancer and hence they were used to count the number of comorbidities.63-67 Categorical
variables which depicted whether a patient had a cardiovascular disease and hepatic disease
were also used in the analyses. These variables were created from ICD-9 and ICD-10 codes of the
Medical Condition files. A categorical variable was created which indicated whether the cancer
patient had a renal disease diagnosis or did not have a renal disease diagnosis and was used as the
main independent variable. Apart from the covariates, complex survey variables were also used
in selected analyses to have unbiased estimates which would account for the survey design and
survey non-response.68 Complex survey variables included a pooled person-level weight, variance
estimation primary sampling unit and a sampling stratum required for variance estimation. Since
this study spans over 10 years, the pooled person-level weight was calculated by dividing the
person-level weight by 10.
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Health related quality of life (HRQoL) is measured in MEPS using Short Form Health
Survey-12 version two (SF-12v2) measured in rounds 2 and 4 of a panel. The SF-12v2 measures the
following eight concepts: physical functioning, role limitations resulting from physical health
problems, bodily pain, general health, vitality (energy/fatigue), social functioning, role limitation
resulting from emotional problems, and mental health with 12 questions including “How often
physical health or emotional problems interfered with social activities”, “Whether they
accomplished less than they would like at work or other regular activity as a result of their
physical health”.76 Responses to these questions are combined to form two summary scores:
Physical Component Summary (PCS) and Mental Component Summary (MCS). PCS is presented
as a continuous variable which ranges from 4.48 to 70.51 and MCS is presented as a continuous
variable which ranges from 3.71 to 75.6. A higher score is indicative of a better HRQoL. The
reliability of SF-12 instrument was high (Cronbach’s alpha of 0.89 for PCS and 0.88 for MCS) in
the cancer patients in US.77 PCS and MCS are the patient reported outcomes which were the
dependent variables in this study. PCS and MCS scores were measured in rounds 2 and 4 of the survey
and hence each individual had 2 scores of PCS and MCS scores. Hence average PCS and average MCS score
were used as the outcome variables for this aim.
STATISTICAL ANALYSES
Test for normality for PCS scores (p < 0.01) and MCS scores (p < 0.01) showed that the
outcome variables were fairly normally distributed and hence parametric tests were used for
analyses. Unadjusted analyses were done using SAS procedure PROC SURVEYMEANS. A multiple
linear regression model was built to determine the mean PCS and MCS in both groups while
controlling for the independent variables mentioned above. Means of PCS and MCS were
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compared using PROC SURVEYREG. The difference between the means of 2 groups were tested
using T-test and SAS procedure PROC SURVEYREG. The model for multivariate linear regression
was:
y = β0 + β1Age + β2Sex + β3Race + β4Marital Status + β5Census Region + β6Income + β7Insurance
Status + β8Employment Status + β9Smoking Status + β10Health Status + β11Number of
comorbidities + β12Hepatic disease indicator + β13Cardiovascular disease indicator + β13Renal
disease indicator + ε0
y = PCS / MCS score
The complex sampling design of the MEPS dataset was considered by using variables
which account for variance estimation strata, person level weights and primary sampling unit. A
significance level of 0.05 was used. SAS v9.4 was used for statistical analyses and MS Excel was
used for data visualization.
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9.2 RESULTS
Health-related quality of life was calculated using mean PCS and MCS scores in both the
groups of patients i.e., patients with renal disease and without renal disease. The mean
unadjusted scores are summarized below in Table 11. Unadjusted analyses showed that patients
with renal disease had a lower mean PCS (40.57 vs 45.38) and MCS scores (50.39 vs 51.47). We
did a multivariate analysis by adjusting for sociodemographic, economic and clinical
characteristics. The results are summarized in Table 12. The results of adjusted analyses were
similar results to unadjusted analyses. Patients without renal disease had a higher PCS score by
4.73 points than a patient with renal disease while controlling for other factors. The difference in
scores was statistically significant (p < 0.0001). On average, patients without renal disease had a
higher MCS score by 1.06 points than a patient with renal disease while controlling for other
factors and this difference in scores was also statistically significant (p < 0.0001).
Table 11: Unadjusted mean HRQoL scores in cancer patients with renal disease and without
renal disease in non-institutionalized US population
HRQoL
Renal
Sample
Mean
Std. Error of
95% CI for Mean
measure
Disease
size
Mean
PCS
Present
1800
40.57
0.3238
39.93
41.21
Absent
9641
45.38
0.1796
45.03
45.74
MCS
Present
1800
50.39
0.3154
49.77
51.01
Absent
9641
51.47
0.1333
51.21
51.73

Table 12: Adjusted mean HRQoL scores in cancer patients with renal disease and without
renal disease in non-institutionalized US population
HRQoL
Renal
Sample
Mean
Std. Error of
95% CI for Mean
measure
Disease
size
Mean
PCS
Present
1786
40.52
0.2213
40.08
40.95
Absent
9431
45.25
0.1494
44.96
45.55
MCS
Present
1786
50.31
0.1324
50.05
50.57
Absent
9431
51.37
0.0746
51.22
51.52
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9.3 DISCUSSION
To our knowledge, this analysis is the first to quantify HRQoL of noninstitutionalized
cancer patients at the national level. It provides vital information to assess the impact of renal
diseases in cancer patient in the US from a new perspective: quality of life. Previous studies have
shown that renal diseases have an impact on mortality.78 Our study shows that renal diseases
also have an impact on quality of life of cancer patients, specifically 4.73 points decrease in PCS
score and 1.06 points decrease in MC-12S score. A previous study has suggested that increase in
HRQoL scores is associated in decrease in healthcare expenditure in cancer patients. 84
A one-point increase in MCS score was associated with 2% decrease in medical expenditures in
all types of cancer. The association of MCS and medical expenditure was not varied by cancer
type. There was no significant association between MCS and frequency of healthcare utilization.
A one-point increase in PCS score was associated with 6% decrease in medical expenditures in
prostate cancer, 4% decrease in medical expenditures in skin cancer and 1% decrease in medical
expenditure on other types of cancer. A one-point increase in PCS score was associated with 1%
decrease in frequency of healthcare utilization in all types of cancer patients and this association
did not differ by cancer type.
A comparison of the PCS and MCS scores for the different populations is shown in the
Table 13 below. The results were similar to what was reported by Abdel-Kader et al. which
estimated HRQoL in patients with end stage renal diseases (ESRD) and chronic kidney disease
(CKD)55. They found that patients with ESRD had a mean PCS score of 36.6 and mean MCS score
of 44.6. Patients with CKD had mean PCS score of 39.3 and mean MCS score of 44.0. Similar to
patients with ESRD and CKD in the Abdel-Kader et al study, cancer patients in our study reported
64

worse physical health than mental health status. In our study which included cancer patients, the
PCS and MCS score was higher than that reported for adults with CKD only or ESRD only in the
study by Abdel-Kader et al.55 These findings indicate that cancer patients with and without
comorbid renal diseases report better HRQoL than adults with only CKD or ESRD. These findings
are similar to the study by Naylor et al. which indicate that patients on CKD have worse outcomes
than cancer patients.79
Our study had some limitations. Firstly, this study is a cross sectional study and hence
causality cannot be inferred. The associations that have been found between the predictors and
outcomes could not be proven true over a longitudinal duration. Secondly, since MEPS is a patient
reported survey, there may be some self-reporting bias, where individuals tend to report
inaccurate or false information.75
Table 13: Comparison of PCS and MCS Scores across different population based on
previous literature
Population
General
Cancer
Cancer
General
General
80
population
patients
patients with population
population
55
without renal renal disease with CKD
with ESRD55
disease
Mean PCS
50.04
45.25
40.52
39.3
36.6
Scores
Mean MCS
51.50
51.37
50.31
44.0
44.6
Scores

Thirdly there may also be recall bias where participants do not remember previous events
or experiences accurately or omit details.75 Fourthly, the design of data collection is such that
one member of the household answers the survey for all the other members of the household
which may lead to errors.75 We could not exclude individuals with a prior renal diagnosis because
of missing data for age of diagnosis of cancer and renal disease. We have assumed that all the
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patients who were diagnosed with renal disease were treated for it. The study could not establish
an association of cancer therapies and adjuvant drugs to renal disease in cancer patients. Finally,
we could not account for disease severity. It is intuitive that individuals with severe disease would
have worse outcomes. The quality of life could be associated with only cancer and not renal
disease. Our study did not assess the HRQoL using disease-specific questionnaire like The Kidney
Disease Quality of Life survey (KDQOL) which would have given a more responsive and clinically
useful than generic quality of life scale like SF-12 v2.81 In 2018, the SF-12v2 was replaced by the
Veteran’s RAND 12-item (VR-12) and was administered to individuals who identified as Veterans
in Round 1 of the interviews. The stage of cancer and type of cancer could also have some effect
on the quality of life of cancer patients and we could not control for that in our study.
Despite these limitations, our study had some strong implications. None of the studies
have evaluated HRQoL associated with renal diseases in cancer patients. Previous studies have
shown that incorporating of early palliative care the patient’s increase quality of life.54,82 Thus,
we encourage clinicians and other stakeholders to integrate early palliative care to relieve
symptom burden which would improve quality of life.
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APPENDIX
Table 1: International Classification of Diseases, Tenth Revision (ICD-10) Codes to identify
cancer patients
C00-C14 Malignant neoplasms of lip, oral C73-C75 Malignant neoplasms of thyroid and
cavity and pharynx
other endocrine glands
C15C26

Malignant neoplasms of digestive C76organs
C80

C30-C39

Malignant neoplasms of
respiratory and intrathoracic
organs

C7A

Malignant neoplasms of ill-defined,
other secondary and unspecified
sites
Malignant neuroendocrine tumors

C40C41

Malignant neoplasms of bone
and
articular cartilage
Melanoma and other malignant
neoplasms of skin
Malignant neoplasms of
mesothelial and soft tissue
Malignant neoplasms of breast

C7B

Secondary neuroendocrine tumors

C81C96
D00D09
D10D36
D37-D48

Malignant neoplasms of lymphoid,
hematopoietic and related tissue
In situ neoplasms

C43C44
C45C49
C50C51-C58

Malignant neoplasms of female
genital organs

C60C63
C64C68
C69-C72

Malignant neoplasms of male
genital organs
Malignant neoplasms of urinary
tract
Malignant neoplasms of eye,
brainand other parts of central
nervous
system

D3A

Benign neoplasms, except benign
neuroendocrine tumors
Neoplasms of uncertain behavior,
polycythemia vera and
myelodysplastic
syndromes
Benign neuroendocrine tumors

D49

Neoplasms of unspecified behavior

Table 2: International Classification of Diseases, Ninth Revision (ICD-9) Codes to identify
cancer patients
140Malignant neoplasms of lip, oral 200Malignant neoplasms of lymphatic
149
cavity and pharynx
209
and hematopoietic tissue
150Malignant neoplasms of digestive 210Benign neoplasms
159
organs and peritoneum
229
160Malignant neoplasms of
230Carcinoma in situ
165
respiratoryand intrathoracic
234
78

organs
170176
179189
190199

Malignant neoplasms of bone,
235connective tissue, skin and breast 238
Malignant neoplasms of
239
genitourinary organs
Malignant neoplasms of other
andunspecified sites

Neoplasms of uncertain behavior

N00N08
N10N16
N17N19

Glomerular diseases

Urolithiasis

N20N23
Renal tubulo-interstitial diseases N25N29
Acute kidney failure and chronic N30kidney disease
N39

Neoplasms of unspecified nature

Other disorders of kidney and
ureter
Other diseases of the urinary
system

Table 4: International Classification of Diseases, Ninth Revision (ICD-9) Codes to identify renal
diseases
580-589 Nephritis, Nephrotic Syndrome, 590-599 Other diseases of urinary system
and Nephrosis
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Table 5: Overview of covariates used in study
Variable name in study
Variable name in MEPS Operationalization
Age
AGEyyX
18 – 44 years, 45 – 64 years, 65+ years
Sex
SEX
Male, Female
Race
RACEV1X, RACEX
White, Black, Other races
Marital status
MARRY31X
Married, Never married, Divorced /
Widowed / Separated
Census region
REGIONyy
Northeast, Midwest, South, West
Income
TTLPyyX
Low, Middle, High
Insurance
INSCOVyy
Private, Public, Uninsured
Education
HIDEG, EDUYRYDG
No school or less than highschool,
Highschool, College or above
Employment status
EMPST31
Employed, Unemployed
Health Status
RTHLTH31
Excellent, Very Good, Good, Fair, Poor
Smoking status
ADSMOK42, OFTSMK53 Smoker, Non-smoker
Number of comorbidities Multiple variables
0, 1, 2, 3, 4+
Hepatic Disease
ICD10CDX, ICD9CODX
Present, Absent
Cardiovascular Disease
ICD10CDX, ICD9CODX
Present, Absent
yy – represents the year example AGE17X for age as of 2017
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